Phase 2 N=21 Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
Actinic Keratosis
Primary: Number of Responders — 19 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=551 Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
Keratosis
Primary: Number of Participants Who Experienced an Adverse Event — 472 participants
Phase 3 N=450 Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp
Actinic Keratosis
Primary: Number of Participants With Complete Clearance of AKs 8 Weeks After Randomisation — 43; 9; 25; 5 participants — p=0.001
Phase 3 N=60 Cryosurgery and Cream Combination for Actinic Keratosis
Actinic Keratosis
Primary: Number Participants With 100% Clearance — 12; 13 Participants
Phase 3 N=490 Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)
Actinic Keratosis
Primary: Number of Participants With Complete Clearance of AK Lesions — 55; 41; 9 participants
Phase 3 N=26 Actinic Keratoses Treatment With Metvix® in Combination With Light
Actinic Keratoses
Primary: Mean Change From Baseline in Total Number of Treated Mild Lesions Per Side at Week 12 — 19.6; 20.0 number of lesions — p=0.8460
Phase 3 N=479 Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)
Actinic Keratoses
Primary: Number of Participants With Complete Clearance of AK Lesions — 57; 49; 10 participants
Phase 4 N=27 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses
Actinic Keratoses
Primary: Change From Baseline in Actinic Keratoses Count at 4-8 Weeks Post-treatment — -73.2; -62.0 Percent change
Phase 2 N=100 ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis
Actinic Keratosis
Primary: Treatment Success at End of Study Visit — 66.7; 65.2; 76.0; 66.7 percentage of participants — p=0.799
Phase 2 N=168 Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
Actinic Keratosis
Primary: Percentage of Participants With Complete Response of Actinic Keratosis — 43; 32 percentage of participants
Phase 3 N=329 A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp
Actinic Keratosis
Primary: Complete Clearance of AKs at Week 11 — 101; 80 participants
N/A N=20 Efficacy and Safety of Tixel Treatment on Facial and/or Scalp Actinic Keratoses.
Actinic Keratoses
Primary: Efficacy of Tixel for Treatment of Actinic Keratosis — -90.4 percentage change
Phase 3 N=351 A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
Actinic Keratosis
Primary: Percentage of Participants With Complete (100%) Clearance of Actinic Keratosis (AK) Lesions — 13; 54 percentage of participants — p=<0.0001
Phase 4 N=30 Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses
Actinic Keratosis
Primary: Percent Change in the Number of Actinic Keratoses — -75 % change in number of actinic keratoses
Phase 3 N=255 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
Actinic Keratoses
Primary: Patients With Complete Clearance of Actinic Keratosis (AKs) — 35; 6 Participants — p=<0.0001
Phase 3 N=203 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
Actinic Keratoses
Primary: Proportion of Patients With Complete Clearance of Actinic Keratoses (AK) Lesions — 42; 5 participants — p=0.001
Phase 2 N=235 Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)
Actinic Keratosis
Primary: Complete Clearance Rate — 14; 7; 13; 8 participants — p=0.0041
Phase 2 N=189 Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively
Actinic Keratosis
Primary: Number of Participants Experiencing DLTs (Dose Limiting Toxicities) Based on LSRs (Local Skin Reactions) — 9; 0; 11 Participants
Phase 3 N=557 Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face
Actinic Keratoses
Primary: Percentage of Participants With Complete Response at Week 12 — 25.3; 23.0 percentage of participants
Phase 3 N=351 A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp
Actinic Keratoses
Primary: Percentage of Participants With Complete (100%) Clearance of Actinic Keratosis (AK) Lesions — 5; 44 percentage of participants — p=<0.0001
Phase 3 N=20 Short Incubation Methylaminolevulinate Photodynamic Therapy Without Occlusion
Actinic Keratosis
Primary: Mean Number of Facial Actinic Keratoses at Week 12 — 2.70 Lesions
Phase 2 N=165 The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses
Actinic Keratoses
Primary: Objective Response of the Marker Actinic Keratosis, Defined as Histologically Complete or Partial Clearance. — 22; 17; 19; 25 participants — p=0.60
Phase 2 N=265 A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
Actinic Keratosis
Primary: Incidence of AEs Recorded Throughout the Study — 12; 12; 8; 11 participants
N/A N=7 Microwave Therapy for Treatment of Precancerous Actinic Keratoses
Actinic Keratoses · Precancerous Skin Lesion
Primary: Resolution of AK Lesions Following Microwave Treatment — 73; 2; 73; 7 AK lesions
Phase 3 N=307 Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
Actinic Keratosis
Primary: Percentage of Participants With Complete Clearance of Actinic Keratosis (AK) — 31.3; 1.0 percentage of participants — p=<0.001
Phase 2 N=33 Study of SOR007 Ointment for Actinic Keratosis
Actinic Keratosis
Primary: Number of Participants With Treatment Emergent Adverse Events — 2; 1; 3; 1 Participants
N/A N=10 Photodynamic Therapy With Levulan® +/- Topical Retinoid Pre-Treatment In The Treatment Of Actinic Keratoses
ACTINIC KERATOSES
Primary: Change in Lesion Counts in 25 cm2 Target Area Relative to Baseline. — -72; -37.5 lesions
Phase 2 N=69 Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
Actinic Keratosis
Primary: Part 1: Participants Experiencing Dose Limiting Toxicity (DLT) Based on Local Skin Responses (LSRs) — 0; 0; 2; 1 Participants
Phase 2 N=83 Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis
Actinic Keratosis
Primary: Complete Clearance Rate — 7; 9 Participants
Phase 3 N=278 A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
Actinic Keratosis
Primary: Complete Clearance of Actinic Keratoses (AK) Lesions — 67; 7 participants — p=<0.001